ArticleOsteoarthritis and cartilage open2026
Emerging concepts in osteoarthritis and musculoskeletal diseases: Insights from the University of Debrecen Musculoskeletal Symposium 2025.
Article in Osteoarthritis and cartilage open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To highlight the key translational advances and interdisciplinary discussions from the 2025 University of Debrecen Musculoskeletal Symposium (UD-MUSK), focusing on osteoarthritis (OA) and related musculoskeletal (MSK) diseases. Method: The UD-MUSK Symposium convened international and local experts for keynote presentations and scientific dialogue spanning OA and MSK disease mechanisms, translational therapies, and tissue regeneration. Core topics included extracellular matrix (ECM) remodelling, cell/gene therapies, animal disease models, chronic stress, autoimmunity, immunotherapies, and muscle and stem cell biology, reflecting the Symposium's broad interdisciplinary spectrum. Results: ECM proteomics revealed degradation fragments that act as drivers and potential modulators of OA, offering new biomarkers and therapeutic targets. Advances in cell- and gene-based therapies were presented, including the use of growth differentiation factor 6 (GDF6) and CRISPR approaches for cartilage and intervertebral disc repair. Large animal models simulating spatio-temporal changes in human OA, and studies demonstrating chronic stress-accelerated OA via neuroendocrine mechanisms, were highlighted. Novel strategies in immune modulation, such as chimeric antigen receptor (CAR) T cell therapy for autoimmune myopathies, alongside research on muscle regeneration and circadian regulation by mechanical loading, further exemplified the translational breadth of the meeting. Conclusion: The symposium underscored the value and need of integrating molecular research and disease modeling. Interdisciplinary collaboration continues to enhance understanding of MSK disease mechanisms and supports development of targeted, regenerative therapies with translational potential for OA and related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.